Literature DB >> 19616746

Microscopic gold particle-based fiducial markers for proton therapy of prostate cancer.

Young Kyung Lim1, Jungwon Kwak, Dong Wook Kim, Dongho Shin, Myonggeun Yoon, Soah Park, Jin Sung Kim, Sung Hwan Ahn, Jungwook Shin, Se Byeong Lee, Sung Yong Park, Hong Ryeol Pyo, Dae Yong Kim, Kwan Ho Cho.   

Abstract

PURPOSE: We examined the feasibility of using fiducial markers composed of microscopic gold particles and human-compatible polymers as a means to overcome current problems with conventional macroscopic gold fiducial markers, such as dose reduction and artifact generation, in proton therapy for prostate cancer. METHODS AND MATERIALS: We examined two types of gold particle fiducial marker interactions: that with diagnostic X-rays and with a therapeutic proton beam. That is, we qualitatively and quantitatively compared the radiographic visibility of conventional gold and gold particle fiducial markers and the CT artifacts and dose reduction associated with their use.
RESULTS: The gold particle fiducials could be easily distinguished from high-density structures, such as the pelvic bone, in diagnostic X-rays but were nearly transparent to a proton beam. The proton dose distribution was distorted <5% by the gold particle fiducials with a 4.9% normalized gold density; this was the case even in the worst configuration (i.e., parallel alignment with a single-direction proton beam). In addition, CT artifacts were dramatically reduced for the gold particle mixture.
CONCLUSION: Mixtures of microscopic gold particles and human-compatible polymers have excellent potential as fiducial markers for proton therapy for prostate cancer. These include good radiographic visibility, low distortion of the depth-dose distribution, and few CT artifacts.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19616746     DOI: 10.1016/j.ijrobp.2009.02.076

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  Investigation of dose perturbations and the radiographic visibility of potential fiducials for proton radiation therapy of the prostate.

Authors:  Jessie Y Huang; Wayne D Newhauser; X Ronald Zhu; Andrew K Lee; Rajat J Kudchadker
Journal:  Phys Med Biol       Date:  2011-07-28       Impact factor: 3.609

Review 2.  The physics of proton therapy.

Authors:  Wayne D Newhauser; Rui Zhang
Journal:  Phys Med Biol       Date:  2015-03-24       Impact factor: 3.609

3.  Novel real-time tumor-contouring method using deep learning to prevent mistracking in X-ray fluoroscopy.

Authors:  Toshiyuki Terunuma; Aoi Tokui; Takeji Sakae
Journal:  Radiol Phys Technol       Date:  2017-12-28

4.  A phantom study to contrast and compare polymer and gold fiducial markers in radiotherapy simulation imaging.

Authors:  Daryl Lim Joon; Drew Smith; Mark Tacey; Michal Schneider; Benjamin Harris; Wee Loon Ong; Farshad Foroudi; Trish Jenkins; Morikatsu Wada; Michael Chao; Kym Rykers; Vincent Khoo
Journal:  Sci Rep       Date:  2021-04-26       Impact factor: 4.996

5.  Determination of optimal fiducial marker across image-guided radiation therapy (IGRT) modalities: visibility and artifact analysis of gold, carbon, and polymer fiducial markers.

Authors:  Lydia L Handsfield; Ning J Yue; Jinghao Zhou; Ting Chen; Sharad Goyal
Journal:  J Appl Clin Med Phys       Date:  2012-09-06       Impact factor: 2.102

6.  Knowledge of endoscopic ultrasound-delivered fiducial composition and dimension necessary when planning proton beam radiotherapy.

Authors:  Ferga C Gleeson; Erik J Tryggestad; Nicholas B Remmes; Chris J Beltran; Jon J Kruse; Michael G Haddock; Christopher L Hallemeier; Andrew C Storm; Michael J Levy
Journal:  Endosc Int Open       Date:  2018-06-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.